Magazine article Clinical Psychiatry News

IM Ziprasidone Effective for Youth with Acute Agitation

Magazine article Clinical Psychiatry News

IM Ziprasidone Effective for Youth with Acute Agitation

Article excerpt

SAN DIEGO -- Intramuscular ziprasidone was well tolerated and effective in a group of children and adolescents who were hospitalized for acute agitation, results from a single-center study showed.

"Some of the typical [antipsychotics cause] extrapyramidal symptoms or acute dystonia, especially in drug-naive patients," Dr. Drew H. Barzman said in an interview during a poster session at the annual meeting of the American Academy of Child and Adolescent Psychiatry. "We're dealing with a younger population who are more prone to acute dystonia and acute EPS. Ziprasidone is a possible option."

He and his associates reviewed the medical records of 59 children with a mean age of 14 years who were admitted to the psychiatric unit of Cincinnati Children's Hospital Medical Center for acute agitation between Jan. 1, 2002 and July 11, 2005 and who received intramuscular ziprasidone (Geodon). The study marks an off-label use of the drug. According to prescribing information from the ziprasidone's manufacturer, Pfizer Inc., the safety and efficacy of the drug in pediatric patients has not been established.

The most common primary diagnosis in patients was bipolar disorder (37%), followed by major depressive disorder (20%), mood disorder not otherwise specified (20%), and psychotic disorder (20%). …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.